secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001829126-24-004310
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa
----------------------------------------------------------------------------

- Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.
- This is Nexalin's second regulatory approval outside China in 2024.
- Brazil has >215M population, >35M with mental health disorders; 9th largest economy.
- CEO says approval is springboard into other South American markets; distributor talks underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/0001829126-24-004310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/nexalintech_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-004310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer